Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Dar© Bioscience and Theramex Announce Co-Development for Contraceptive Implant
Details : Under the licensing agreement, Dare will develop Casea S (etonogestrel), a potential first-in-category contraceptive candidate for women.
Product Name : Casea S
Product Type : Hormone
Upfront Cash : Undisclosed
February 20, 2025
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Organon
Deal Size : Undisclosed
Deal Type : Demerger
Merck Announces Completion of Organon & Co. Spinoff
Details : Organon will pursue sustainable growth in Women’s Health led by patent-protected Nexplanon (etonogestrel implant) franchise and fueled by its leading contraceptive and fertility businesses. It expects to establish a leading position in Biosimilars focu...
Product Name : Nexplanon
Product Type : Hormone
Upfront Cash : Undisclosed
March 06, 2021
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Organon
Deal Size : Undisclosed
Deal Type : Demerger
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Financing
Details : Organon’s commercial strategy will center around Nexplanon (etonogestrel implant), its long-active reversible contraceptive, that delivered approximately $1.6 billion in global sales in 2020.
Product Name : Nexplanon
Product Type : Hormone
Upfront Cash : Undisclosed
March 05, 2021
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Zentiva
Deal Size : $2.2 million
Deal Type : Agreement
Mithra to Commercialize Myring In France, Poland And UK
Details :
Product Name : Myring
Product Type : Hormone
Upfront Cash : Undisclosed
June 07, 2020
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Zentiva
Deal Size : $2.2 million
Deal Type : Agreement
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Gynial
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mithra Pharmaceuticals and Gynial Sign Commercialization Agreement for Myring™ in Switzerland
Details :
Product Name : Myring
Product Type : Hormone
Upfront Cash : Undisclosed
May 05, 2020
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Gynial
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Newco
Deal Size : $9.0 million
Deal Type : Demerger
Details : Merck will retain its current growth pillars of Oncology, Vaccines, Hospital and Animal Health and continue to invest in research and development of breakthrough innovations across all areas of science.
Product Name : Nexplanon
Product Type : Hormone
Upfront Cash : Undisclosed
May 02, 2020
Lead Product(s) : Etonogestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Newco
Deal Size : $9.0 million
Deal Type : Demerger
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Farmitalia
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mithra Signs LSA for Commercialization of Myring™ in Italy, the Third Biggest Worldwide Market
Details :
Product Name : Myring
Product Type : Hormone
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Farmitalia
Deal Size : Undisclosed
Deal Type : Licensing Agreement